
1. Technology overview
icometrix is a brain imaging AI company founded in 2011 in Leuven, Belgium, as a spin-off from Belgian universities and hospitals, with a US office in Boston. It addresses the need for objective, reproducible measurement of brain MRI in neurological disease.
The icobrain platform extracts quantitative data from brain MRI scans for multiple sclerosis, dementia and Alzheimer's disease, stroke, traumatic brain injury, epilepsy, Parkinson's disease and brain tumors. icobrain aria detects and grades amyloid-related imaging abnormalities (ARIA-E and ARIA-H) in patients on anti-amyloid therapy. Users are hospitals, radiologists, neurologists and pharmaceutical companies running trials.
2. Highlighted features & specifications
- icobrain: quantitative brain MRI analysis for MS, dementia, stroke, TBI, epilepsy, Parkinson's and brain tumors.
- icobrain aria: automated detection and quantification of ARIA-E and ARIA-H with a severity score.
- Longitudinal tracking: follows ARIA and brain changes across successive scans.
- icolung: AI lung analysis launched in 2020.
- icompanion: patient care platform for people with multiple sclerosis.
- Clinical workflow integration: connects to radiology and hospital workflows.
3. Potential application
Memory clinics at Vietnamese tertiary hospitals could use icobrain to quantify brain atrophy on routine MRI. Neurology and MS centers could track lesion and volume change between visits. Hospitals starting anti-amyloid therapy could use icobrain aria for ARIA safety monitoring.
4. Benefits
Gives radiologists and neurologists quantified brain MRI measures instead of purely visual reads.
icobrain aria was validated in a 16-radiologist, 400+ scan study published in JAMA Network Open, with shorter reading time and better inter-reader agreement.
Supports safer prescribing of anti-amyloid treatments through ARIA monitoring.
Serves pharma teams with imaging biomarkers for trials and real-world evidence.
5. Market trends & opportunities
Anti-amyloid Alzheimer's therapies require systematic MRI monitoring for ARIA, creating demand for AI-assisted reading. Large imaging vendors are buying quantitative neuro-imaging software, as shown by GE HealthCare's 2025 agreement to acquire icometrix. Aging populations in Southeast Asia raise the need for dementia imaging tools.
6. Other information
Founded 2011 in Leuven, Belgium, with a US office in Boston. GE HealthCare announced in September 2025 an agreement to acquire icometrix; the site now identifies it as a GE HealthCare company. icobrain aria carries market approval in Europe, Israel, Japan, Switzerland and the UK, and FDA 510(k) clearance.
One platform connecting startups, corporations, research institutions, regions and investors











Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
RETAIL E-COMMERCE: AI AND REAL-TIME DATA ARE TRANSFORMING HOW RETAIL BUSINESSES OPERATE








































